Contagion, Fall 2024 Digital Edition

Read more about the case of a 71-year-old man who was admitted after presenting with cold-like symptoms for 3 weeks.

New therapeutics offer some hope in this emerging market.

In a world heavily focused on therapeutic options for multidrug-resistant gram-negative organisms, the emergence of antimicrobial resistance among enterococci is often an under-recognized risk.

Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.

There has been an emergence of extracorporeal membrane oxygenation-associated infections. Here is a review of how to define them and clinical management of this heterogeneous syndrome.

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.

Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.

ID clinicians must be paid for time spent conducting unbillable work for OPAT services.

This systematic review focuses on breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological cancers, like acute leukemia, or those who have undergone stem cell transplants. Despite prophylactic antifungal treatments (usually with voriconazole or posaconazole), bIFIs remain challenging due to their complexity and high mortality rates.

With AMR being a global priority, biosecurity-type policy around resistance may be part of the solution.

View our interactive Fall 2024 digital edition.